Pharmaceutical

Atsena closes $150m in Series C round to progress gene therapy

Atsena Therapeutics has completed an oversubscribed Series C financing round, raising $150m to support the advancement of ATSN-201.

Apr 4, 2025 - 06:00
Atsena closes $150m in Series C round to progress gene therapy
Atsena Therapeutics has completed an oversubscribed Series C financing round, raising $150m to support the advancement of ATSN-201.
Read the original article

Tags:

Previous Article

ABPI calls on UK Government to resolve “VPAG crisis”

Next Article

IO360 summit: CAR-T cell therapy applications beyond blood cancer

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

IBI-343 by Innovent Biologics for Solid Tumor: Likeliho...

Jun 20, 2024

Scorpion Therapeutics secures $150m for oncology pipeline

Scorpion Therapeutics secures $150m for oncology pipeline

Jul 18, 2024

From fusion to retooling cancer trials, Eric Lander wants his new group to ‘go after big problems’

From fusion to retooling cancer trials, Eric Lander wan...

May 13, 2023